Novartis leads with a $1.1 billion bet
The day's biggest deal came out of Switzerland. Novartis is acquiring UK biotech Myricx Bio for $1.1 billion upfront, according to Endpoints News, which reported the transaction was announced Monday. Novartis is buying Myricx's next-generation antibody-drug conjugate platform — a class of cancer drugs designed to deliver toxic payloads directly to tumor cells. It's a sizable upfront commitment that signals continued appetite among large pharma for cutting-edge oncology technology.
Dealmaking and the market's uneven verdict on AI drug discovery
Artificial intelligence remained the connective thread across today's corporate moves — with markets rewarding some players and shrugging at others. Takeda Pharmaceutical (TSE:4502) saw shares climb 5.3% after announcing a new AI drug discovery deal with Insilico, according to simplywall.st, which framed the jump as an investor endorsement of the partnership. Insilico is having a moment: the company is also set to spotlight its AI-driven drug discovery progress at Geneva's high-profile AI for Good Summit, per a News-Medical report.
Not everyone is enjoying the same enthusiasm. Recursion Pharmaceuticals, one of the most visible companies staking its future on AI-discovered medicines, is finding that investor excitement hasn't translated into share-price strength — a reminder that the technology's promise and the stock market's patience don't always move together.
AI reaches deeper into the biology of medicine
Beyond the deal desk, AI is pushing further into the science itself. A report highlighted by Nature describes how AI is being used to decode protein–ligand binding — the molecular "handshake" between a small molecule (the ligand) and its target protein that underlies how most drugs actually work. Separately, Technology Networks reports on AI and machine learning moving genomics beyond raw sequence analysis toward genuine biological insight.
On the clinical frontier, a new report is drawing attention to COMPASS, an AI approach being examined for its ability to predict how patients respond to immunotherapy across multiple cancer types, according to Oncodaily — potentially a step toward matching the right patients to the right treatments.
From the operating room to the pill counter
AI's commercial footprint in care delivery is expanding fast. The market for AI in the operating room is projected to hit $3.29 billion by 2030, according to a GlobeNewswire forecast that describes the trajectory as "exponential growth." And automation is arriving at the pharmacy counter too: Interesting Engineering published video of what's billed as the world's first fully robotic pharmacy, a facility that fills prescriptions without a human hand touching the pill bottle.
Nature also examined how AI and machine learning are being applied to precision nutrition — the effort to tailor dietary advice to individuals as the one-diet-fits-all idea fades.
The strategists weigh in
Two notable voices framed the bigger picture. Anthropic's chief executive sat down with STAT to discuss how AI might reshape biotechnology. And the Salk Institute, the storied San Diego biomedical research center, is leaning hard into AI to power its life sciences work — a strategic pivot playing out even as federal research funding faces new pressures.
Taken together, today paints a familiar but sharpening picture: capital is flowing toward next-generation therapeutics and AI-powered discovery, the science is getting more molecular, and automation is reaching from the lab bench to the operating table to the pharmacy shelf — while the market keeps a discerning eye on which bets actually pay off.